Clinical trial NCT03408613: Obstructive Sleep Apnea and Glucose Metabolism
Official title: Obstructive Sleep Apnea and Glucose Metabolism
Study type: INTERVENTIONAL
Overall status: SUSPENDED
Phase: NA
Conditions: Sleep Apnea
Glucose Metabolism Disorders
Keywords: Obstructive Sleep Apnea
Glucose Metabolism
Lead sponsor: University of Missouri-Columbia
Sponsor class: OTHER
First posted: 2018-01-24
Enrollment: 80
Sex: ALL
Minimum age (years): 30
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Many adults who are overweight have obstructive sleep apnea (OSA) which disrupts sleep and makes it difficult to breath during the night. OSA increases the risk for a person to become insulin resistant and diabetic. It is not known why OSA causes this problem, i.e., whether it is disrupted sleep or lack of oxygen., which can change how the body handles glucose in adipose tissue, muscle tissue and liver.

The purpose of this research study is to determine the key issues and mechanisms responsible for dysregulated glucose metabolism in people with OSA. The investigators will do this by comparing glucose metabolism in people who have OSA, and those who do not, and by evaluating the effect of treating OSA by providing continuous positive airway pressure (CPAP) or simply oxygen during the night.

The proposed study will evaluate the primary causes(s) (hypoxia, sleep fragmentation, or both) and pathophysiological mechanisms responsible for the OSA-associated metabolic abnormalities. Knowing the primary cause of Obstructive Sleep Apnea and pathophysiological mechanisms responsible for the OSA-associated metabolic abnormalities could help develop potentially novel therapeutic strategies to provide treatment for adults in improving OSA and associated comorbidities.


Eligibility criteria: General Inclusion Criteria (for all subjects):

* Age: ≥30 and ≤70 years,
* BMI: ≥30 and ≤45 kg/m2 or body fat ≥ 30 % for women and ≥ 25 % for men,
* Maximum body circumference \<170 cm
* Weight stable (≤2% change)
* Untrained (≤1 h of structured exercise/wk) for at least 3 months before entering the study
* No diabetes (fasting blood glucose \<126 mg/dl, 2h oral glucose tolerance test (OGTT) glucose \<200 mg/dl, HbA1c ≤6.5%)

Sleep-related inclusion criteria:

Subjects without OSA:

* AHI \<5/h of sleep;
* Oxygen desaturation index \<3/h
* No known sleep disorders and periodic limb movement arousal index \<15/h during polysomnography
* Reported sleep duration ≥6 h per night
* Regular sleep schedules (i.e. bedtime between 8 pm and 12 am and wake-time between 4 am and 8 am on all days of the week)

Subjects with OSA

* AHI ≥10/h of sleep (i.e., moderate to severe OSA)
* Oxygen desaturation index ≥4/h;
* No polysomnogram finding that would trigger immediate PAP treatment as per standard operating protocol in our sleep medicine center (a single SaO2 \<50%, SaO2 \<70% for \>2 minutes, electrocardiogram pause \>5 sec, or ventricular tachycardia \>30 sec), because of the risk of a potentially adverse outcome if they are not randomized to the PAP group
* Periodic limb movement arousal index \<15/h during polysomnography,
* Reported sleep duration ≥6 h per night,
* Regular night-time sleep schedules, defined as bedtime between 8 pm and 12 am and wake-time between 4 am and 8 am on all days of the week.

General Exclusion Criteria (for all subjects):

* Current treatment for previously diagnosed OSA;
* Self-reported severe difficulty sleeping in unfamiliar environments;
* Metal implants that are incompatible with magnetic resonance imaging;
* Controlled substances, tobacco products, dietary supplements, or medications known or suspected to affect sleep, breathing, upper airway muscle physiology, or glucose metabolism
* Evidence of disease (e.g., diabetes, congestive heart failure; chronic obstructive pulmonary disease; hypoventilation, defined as daytime partial pressure of carbon dioxide (pCO2) \>45 mm Hg; major neurological or neuromuscular disorders; cancer; uncontrolled hypertension; etc.);
* Contraindications to supplemental oxygen or PAP (e.g., recent trans-sphenoidal surgery).
* Unwillingness or inability to provide informed consent
* Study physician considers subject to be unable to safely complete the study protocol

Primary outcomes:
measure: Insulin mediated glucose disposal
timeFrame: 3 months
Secondary outcomes:
measure: β-cell function
timeFrame: 3 months
measure: Tissue oxygenation
timeFrame: 3 months
measure: Body composition analysis
timeFrame: 3 months
Other outcomes:
Locations:
city: Saint Louis
country: United States
facility: Washington University School of Medicine
state: Missouri
Study officials:
affiliation: Washington University School of Medicine
name: Bettina Mittendorfer, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Cao C, Koh HE, Van Vliet S, Patterson BW, Reeds DN, Laforest R, Gropler RJ, Mittendorfer B. Increased plasma fatty acid clearance, not fatty acid concentration, is associated with muscle insulin resistance in people with obesity. Metabolism. 2022 Jul;132:155216. doi: 10.1016/j.metabol.2022.155216. Epub 2022 May 13.
citation: van Vliet S, Koh HE, Patterson BW, Yoshino M, LaForest R, Gropler RJ, Klein S, Mittendorfer B. Obesity Is Associated With Increased Basal and Postprandial beta-Cell Insulin Secretion Even in the Absence of Insulin Resistance. Diabetes. 2020 Oct;69(10):2112-2119. doi: 10.2337/db20-0377. Epub 2020 Jul 10.